{"id":"artemisinin","rwe":[{"pmid":"41903303","year":"2026","title":"Artesunate protects against ischemic stroke through THBS2/CD36/TLR4 pathway.","finding":"","journal":"International immunopharmacology","studyType":"Clinical Study"},{"pmid":"41901260","year":"2026","title":"NovelHTI: An Interpretable Pathway-Enhanced Framework for De Novo Target Prediction of Medicinal Herbs via Cross-Scale Heterogeneous Information Fusion.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41893529","year":"2026","title":"Evaluating Toxicity and Anti-Osteogenic Activity of Artemisinin-Inspired Endoperoxides in Zebrafish Larvae.","finding":"","journal":"Toxics","studyType":"Clinical Study"},{"pmid":"41891011","year":"2026","title":"Sustained High Prevalence of Multiple Antimalarial Drug Resistance Markers in Uganda in 2023-24.","finding":"","journal":"medRxiv : the preprint server for health sciences","studyType":"Clinical Study"},{"pmid":"41890835","year":"2026","title":"Recurrent parasitemias with artemisinin partial resistance mutations during the 2024 Ethiopia malaria resurgence: a case series.","finding":"","journal":"Research square","studyType":"Clinical Study"}],"tags":[{"label":"artemisinin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Cytochrome P450 1A2","category":"target"},{"label":"CYP1A2","category":"gene"},{"label":"P01BE01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Spray","category":"form"},{"label":"Active","category":"status"},{"label":"Falciparum malaria","category":"indication"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"phase_3","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"artemef","offLabel":[],"synonyms":["artemisinin","(+)-Artemisinin","arteannuin","artemef","artemisine","artemisinine"],"timeline":[],"brandName":"Artemef","ecosystem":[{"indication":"Falciparum malaria","otherDrugs":[{"name":"artesunate","slug":"artesunate","company":"Amivas"},{"name":"atovaquone","slug":"atovaquone","company":""},{"name":"chloroquine","slug":"chloroquine","company":"Sanofi Aventis Us"},{"name":"halofantrine","slug":"halofantrine","company":"Glaxosmithkline"}],"globalPrevalence":240000}],"mechanism":{"target":"Cytochrome P450 1A2","targets":[{"gene":"CYP1A2","source":"DrugCentral","target":"Cytochrome P450 1A2","protein":"Cytochrome P450 1A2"}],"modality":"Small Molecule","drugClass":"artemisinin","explanation":"Imagine your body's cells as a city under attack by a group of invaders. Artemef is like a special kind of bomb that targets and destroys these invaders, but it's designed to only affect the bad guys and not harm the good cells.","oneSentence":"Artemef works by generating reactive oxygen species that rapidly kill malaria parasites.","technicalDetail":"Artemef's mechanism of action involves the endoperoxide bridge in its molecular structure, which undergoes a redox reaction to form reactive oxygen species (ROS) such as free radicals and singlet oxygen. These ROS then interact with the heme group of the malaria parasite's hemoglobin, leading to the formation of a cytotoxic compound that ultimately kills the parasite."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3871","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ARTEMISININ","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ARTEMISININ","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:49:47.949066","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:42:43.455665+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"artemether","drugSlug":"artemether","fdaApproval":"2009-04-07","relationship":"same-class"},{"drugName":"artesunate","drugSlug":"artesunate","fdaApproval":"2020-05-26","patentExpiry":"Feb 16, 2044","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"artemisinin","indications":{"approved":[{"name":"Falciparum malaria","source":"DrugCentral","snomedId":62676009,"regulator":"FDA","eligibility":"Adults","usPrevalence":null,"globalPrevalence":240000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency2015[INST])"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"artemether","brandName":"artemether","genericName":"artemether","approvalYear":"2009","relationship":"same-class"},{"drugId":"artesunate","brandName":"artesunate","genericName":"artesunate","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07470424","phase":"PHASE1","title":"A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2026-06-01","conditions":["Malaria"],"enrollment":24,"completionDate":"2027-08-01"},{"nctId":"NCT07235033","phase":"PHASE2","title":"Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-23","conditions":["Uncomplicated Plasmodium Falciparum Malaria"],"enrollment":60,"completionDate":"2025-03-19"},{"nctId":"NCT07403643","phase":"PHASE4","title":"Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria","status":"NOT_YET_RECRUITING","sponsor":"Curtin University","startDate":"2026-04","conditions":["Uncomplicated Malaria"],"enrollment":60,"completionDate":"2026-12"},{"nctId":"NCT06967519","phase":"PHASE4","title":"OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-12-18","conditions":["Malaria","Hiv"],"enrollment":380,"completionDate":"2027-12"},{"nctId":"NCT06806956","phase":"","title":"Severe Malaria in Remote Areas- Closing the Evidence Gap","status":"ENROLLING_BY_INVITATION","sponsor":"Tropical Diseases Research Centre, Zambia","startDate":"2024-03-10","conditions":["Severe Malaria"],"enrollment":2016,"completionDate":"2027-04"},{"nctId":"NCT05842954","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-03-07","conditions":["Uncomplicated Plasmodium Falciparum Malaria"],"enrollment":1720,"completionDate":"2025-11-25"},{"nctId":"NCT07362498","phase":"","title":"Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya","status":"COMPLETED","sponsor":"Strathmore University","startDate":"2020-06-01","conditions":["Malaria Falciparum"],"enrollment":316,"completionDate":"2024-01-31"},{"nctId":"NCT07358767","phase":"NA","title":"Impact of Malaria Mass Drug Administration on Malaria Prevalence in Under 15 Children and Pregnant Women","status":"COMPLETED","sponsor":"Noguchi Memorial Institute for Medical Research","startDate":"2021-07-01","conditions":["Malaria"],"enrollment":3300,"completionDate":"2023-03-31"},{"nctId":"NCT05757167","phase":"PHASE4","title":"Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics","status":"RECRUITING","sponsor":"Duke University","startDate":"2023-11-06","conditions":["Malaria,Falciparum","Malaria in Pregnancy","Malaria in Childbirth","Pregnancy","Neonatal Health","Low Birthweight","Stillbirth","Gestational Age and Weight Conditions","Preterm Birth"],"enrollment":2500,"completionDate":"2027-02"},{"nctId":"NCT04080895","phase":"PHASE1","title":"Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2022-11-01","conditions":["Pharmacokinetic","Healthy","Drug Combination"],"enrollment":8,"completionDate":"2025-04-01"},{"nctId":"NCT06872112","phase":"PHASE1","title":"A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension","status":"RECRUITING","sponsor":"Joseph C. Wu","startDate":"2026-01-01","conditions":["Pulmonary Arterial Hypertension (PAH)"],"enrollment":15,"completionDate":"2029-01-01"},{"nctId":"NCT05750459","phase":"PHASE4","title":"Pharmacokinetic Study of IV Artesunate to Treat Children With Severe Malaria","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-11-29","conditions":["Plasmodium Falciparum Infection"],"enrollment":90,"completionDate":"2025-04-01"},{"nctId":"NCT04675931","phase":"PHASE2","title":"To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-03-07","conditions":["Severe Malaria"],"enrollment":254,"completionDate":"2025-08-20"},{"nctId":"NCT04009343","phase":"PHASE2,PHASE3","title":"Pharmacokinetics and Pharmacodynamics of the Gametocytocidal and Post-treatment Chemoprotective Effects of Antimalarials","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2019-06-19","conditions":["Uncomplicated Falciparum Malaria"],"enrollment":182,"completionDate":"2026-12"},{"nctId":"NCT06624631","phase":"PHASE4","title":"PDMC Implementation Trial in Kenya","status":"RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-09-05","conditions":["Severe Malaria","Severe Anemia"],"enrollment":600,"completionDate":"2026-09-30"},{"nctId":"NCT06962319","phase":"PHASE3","title":"Safety of Antimalarials in the FIRst trimEster","status":"RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-09-30","conditions":["Malaria, Pregnancy","Malaria, Antepartum","Malaria (Uncomplicated)"],"enrollment":1510,"completionDate":"2029-08"},{"nctId":"NCT05951595","phase":"PHASE3","title":"A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-09-11","conditions":["Uncomplicated Plasmodium Falciparum Malaria"],"enrollment":1680,"completionDate":"2026-07-31"},{"nctId":"NCT03923725","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-09-01","conditions":["Plasmodium Falciparum Malaria (Uncomplicated)"],"enrollment":2583,"completionDate":"2024-03-15"},{"nctId":"NCT06853184","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of Artesunate","status":"RECRUITING","sponsor":"Amivas Inc.","startDate":"2025-08-01","conditions":["CMV Infection"],"enrollment":90,"completionDate":"2028-06-30"},{"nctId":"NCT04098744","phase":"PHASE2","title":"Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)","status":"RECRUITING","sponsor":"Frantz Viral Therapeutics, LLC","startDate":"2020-09-09","conditions":["CIN 2/3","HPV Infection","Pre-Cancerous Dysplasia","Cervical Dysplasia","HPV Related Disease"],"enrollment":78,"completionDate":"2026-12-31"},{"nctId":"NCT04553705","phase":"PHASE2,PHASE3","title":"Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2020-09-20","conditions":["Covid19","Immunodeficiency"],"enrollment":150,"completionDate":"2021-12-04"},{"nctId":"NCT07022743","phase":"PHASE2","title":"Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Obafemi Awolowo University","startDate":"2025-07-01","conditions":["Chronic Myeloid Leukemia (CML)"],"enrollment":75,"completionDate":"2026-12"},{"nctId":"NCT05343312","phase":"PHASE4","title":"In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2022-03-16","conditions":["Malaria"],"enrollment":870,"completionDate":"2025-07-30"},{"nctId":"NCT06075264","phase":"PHASE2","title":"Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)","status":"RECRUITING","sponsor":"Frantz Viral Therapeutics, LLC","startDate":"2023-12-06","conditions":["Vulvar Diseases","HPV Infection","Vulvar HSIL","Pre-Cancerous Dysplasia","HPV Disease","VIN, Usual Type","VIN 2 of Usual Type","VIN 3 of Usual Type","Vin II","Vin III","VIN Grade 2","VIN Grade 3","High Grade Intraepithelial Neoplasia"],"enrollment":27,"completionDate":"2027-12"},{"nctId":"NCT07095309","phase":"PHASE2","title":"Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Metanoic Health Ltd.","startDate":"2025-08-15","conditions":["Stage II/III Colon Cancer","Bowel Cancer"],"enrollment":120,"completionDate":"2033-07-31"},{"nctId":"NCT07095478","phase":"PHASE2","title":"Safety and Efficacy of Oral Artesunate for Pre-cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Metanoic Health Ltd.","startDate":"2025-08-01","conditions":["CIN 2/3"],"enrollment":28,"completionDate":"2028-06-30"},{"nctId":"NCT05750628","phase":"PHASE2","title":"Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-23","conditions":["Uncomplicated Plasmodium Falciparum Malaria"],"enrollment":327,"completionDate":"2026-06-23"},{"nctId":"NCT06601712","phase":"PHASE4","title":"Post-discharge Malaria Chemoprevention Implementation Trial in Benin","status":"RECRUITING","sponsor":"Institut de Recherche Clinique du Benin","startDate":"2025-07-02","conditions":["Severe Malaria","Severe Anaemia"],"enrollment":648,"completionDate":"2026-12-31"},{"nctId":"NCT05540470","phase":"NA","title":"Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield","status":"COMPLETED","sponsor":"Centre Hospitalier de Cayenne","startDate":"2022-09-12","conditions":["Malaria, Vivax"],"enrollment":1991,"completionDate":"2025-04-25"},{"nctId":"NCT05555862","phase":"PHASE2","title":"Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Frantz Viral Therapeutics, LLC","startDate":"2023-02-10","conditions":["Anal High Grade Squamous Intraepithelial Lesion","Anal Precancerous Condition","AIN 2/3","HPV Infection","Anal Dysplasia","HPV Disease"],"enrollment":17,"completionDate":"2026-12-31"},{"nctId":"NCT06206564","phase":"PHASE2","title":"Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants","status":"RECRUITING","sponsor":"Frantz Viral Therapeutics, LLC","startDate":"2024-01-12","conditions":["Anal High-grade Squamous Intraepithelial Lesion","Anal HSIL","Anal HPV Infection","AIN"],"enrollment":48,"completionDate":"2026-12-31"},{"nctId":"NCT05788094","phase":"PHASE4","title":"ACT vs CQ With Tafenoquine for P. Vivax Mono-infection","status":"RECRUITING","sponsor":"Shoklo Malaria Research Unit","startDate":"2023-06-26","conditions":["Malaria","Malaria, Vivax","Plasmodium Vivax Malaria"],"enrollment":606,"completionDate":"2026-08-31"},{"nctId":"NCT06970600","phase":"NA","title":"Efficacy of Artemether-Lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Under 12 Years at Four Sentinel Sites in Mozambique","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2024-03-07","conditions":["Malaria (Uncomplicated)"],"enrollment":352,"completionDate":"2025-01-31"},{"nctId":"NCT03453840","phase":"PHASE4","title":"Extended Duration Artemether-lumefantrine Treatment for Malaria in Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-02-21","conditions":["Uncomplicated Plasmodium Falciparum Malaria"],"enrollment":305,"completionDate":"2021-08-31"},{"nctId":"NCT04706130","phase":"PHASE4","title":"Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2021-04-15","conditions":["Vivax Malaria"],"enrollment":160,"completionDate":"2024-10-01"},{"nctId":"NCT03300648","phase":"PHASE3","title":"Treating Brain Swelling in Pediatric Cerebral Malaria","status":"COMPLETED","sponsor":"Michigan State University","startDate":"2018-01-08","conditions":["Malaria, Cerebral"],"enrollment":57,"completionDate":"2023-12-31"},{"nctId":"NCT06166498","phase":"PHASE3","title":"Parasite Clearance and Protection From Infection (PCPI) in Zambia","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2024-07-24","conditions":["Malaria"],"enrollment":600,"completionDate":"2025-03-05"},{"nctId":"NCT06347471","phase":"PHASE4","title":"The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy","status":"RECRUITING","sponsor":"Infectious Diseases Research Collaboration, Uganda","startDate":"2024-05-28","conditions":["Falciparum; Malaria"],"enrollment":120,"completionDate":"2026-04"},{"nctId":"NCT04704999","phase":"PHASE4","title":"Southeast Asia Dose Optimization of Tafenoquine","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2024-07-22","conditions":["Plasmodium Vivax Malaria"],"enrollment":700,"completionDate":"2028-02-07"},{"nctId":"NCT05676645","phase":"","title":"Pharmacokinetics of Antimalarials in Breastfeeding Ugandan Mother-infant Pairs","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Liverpool","startDate":"2023-03-20","conditions":["Malaria,Falciparum"],"enrollment":30,"completionDate":"2026-12-25"},{"nctId":"NCT06294912","phase":"PHASE1","title":"A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-18","conditions":["Malaria"],"enrollment":16,"completionDate":"2025-01-06"},{"nctId":"NCT05764746","phase":"PHASE2,PHASE3","title":"Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial","status":"RECRUITING","sponsor":"Muhimbili University of Health and Allied Sciences","startDate":"2023-05-01","conditions":["Uncomplicated Plasmodium Falciparum Malaria"],"enrollment":384,"completionDate":"2024-12-30"},{"nctId":"NCT06555809","phase":"","title":"Evaluation of Artesunate in Infants Being Treated for Severe Malaria","status":"RECRUITING","sponsor":"Amivas Inc.","startDate":"2024-10-06","conditions":["Malaria"],"enrollment":15,"completionDate":"2030-02-28"},{"nctId":"NCT02942277","phase":"PHASE1","title":"Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-21","conditions":["Malaria"],"enrollment":301,"completionDate":"2020-07-15"},{"nctId":"NCT03640403","phase":"PHASE3","title":"Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania","status":"COMPLETED","sponsor":"National Institute for Medical Research, Tanzania","startDate":"2019-03-26","conditions":["Malaria,Falciparum","Anemia"],"enrollment":1555,"completionDate":"2021-12-31"},{"nctId":"NCT06076213","phase":"PHASE4","title":"Test Efficacy Study on the Recommended Antimalarial Drugs in the Democratic Republic of the Congo","status":"COMPLETED","sponsor":"Ministry of Public Health, Democratic Republic of the Congo","startDate":"2023-05-01","conditions":["Uncomplicated Plasmodium Falciparum Malaria"],"enrollment":1260,"completionDate":"2024-09-30"},{"nctId":"NCT05550909","phase":"PHASE2","title":"Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2022-10-17","conditions":["Malaria,Falciparum"],"enrollment":100,"completionDate":"2023-01-26"},{"nctId":"NCT04546633","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-16","conditions":["Uncomplicated Plasmodium Falciparum Malaria"],"enrollment":295,"completionDate":"2024-08-28"},{"nctId":"NCT04661579","phase":"PHASE2","title":"Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy","status":"COMPLETED","sponsor":"PATH","startDate":"2020-11-06","conditions":["Plasmodium Falciparum"],"enrollment":620,"completionDate":"2022-08-17"},{"nctId":"NCT06472258","phase":"NA","title":"Efficacy of Only IV Artesunate Versus IV Artesunate Plus IV Quinine in the Treatment of Severe Malaria in Children: A Comparative Study","status":"COMPLETED","sponsor":"RESnTEC, Institute of Research","startDate":"2023-03-01","conditions":["Malaria"],"enrollment":104,"completionDate":"2023-06-30"},{"nctId":"NCT04280692","phase":"PHASE1,PHASE2","title":"Controlled Human Malaria Infection Transmission Model - Phase A","status":"SUSPENDED","sponsor":"University of Oxford","startDate":"2022-08-22","conditions":["Malaria,Falciparum"],"enrollment":44,"completionDate":"2026-08"},{"nctId":"NCT06424002","phase":"PHASE4","title":"The Impact RTS,S/AS01 Vaccine in School Aged Children RTS,S/AS01 Malaria Vaccine in School Aged Children","status":"NOT_YET_RECRUITING","sponsor":"Kamuzu University of Health Sciences","startDate":"2024-06-01","conditions":["Malaria,Falciparum"],"enrollment":5400,"completionDate":"2024-12-30"},{"nctId":"NCT06300970","phase":"PHASE4","title":"Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-08-09","conditions":["Plasmodium Falciparum","Malaria","Uncomplicated Malaria"],"enrollment":352,"completionDate":"2023-08-16"},{"nctId":"NCT04428385","phase":"NA","title":"Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: TESTsmART Aim 2 - Nigeria","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-03-15","conditions":["Malaria","Febrile Illness"],"enrollment":2205,"completionDate":"2023-02-28"},{"nctId":"NCT04666350","phase":"","title":"Clinical Investigation Study to Evaluate the Consistency and Reproducibility of Two Consecutive Mosquito Feeding Assays","status":"COMPLETED","sponsor":"PATH","startDate":"2021-03-09","conditions":["Malaria"],"enrollment":42,"completionDate":"2021-12-20"},{"nctId":"NCT06179732","phase":"PHASE3","title":"Field Evaluations of Innovative Tools for Vector-borne Disease Control in Conflict-affected Communities","status":"COMPLETED","sponsor":"The Mentor Initiative","startDate":"2023-06-05","conditions":["Malaria","Childhood ALL","Vector Borne Diseases"],"enrollment":2400,"completionDate":"2023-12-31"},{"nctId":"NCT03178643","phase":"PHASE4","title":"Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE)","status":"COMPLETED","sponsor":"Duke University","startDate":"2018-01-23","conditions":["Malaria,Falciparum"],"enrollment":246,"completionDate":"2020-12-16"},{"nctId":"NCT04041973","phase":"NA","title":"Study to Assess Efficacy of Artemether-lumefantrine Prophylaxis Against Forest Malaria in Cambodia (PAL_Cambodia)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-03-11","conditions":["Malaria"],"enrollment":1480,"completionDate":"2021-03-17"},{"nctId":"NCT03939104","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-06-30","conditions":["Plasmodium Falciparum Malaria (Uncomplicated)"],"enrollment":103,"completionDate":"2023-01-28"},{"nctId":"NCT02389374","phase":"PHASE4","title":"A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2014-08","conditions":["Malaria"],"enrollment":181,"completionDate":"2015-03"},{"nctId":"NCT04695197","phase":"PHASE3","title":"Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2021-01-08","conditions":["Covid-19","Malaria"],"enrollment":143,"completionDate":"2024-02-20"},{"nctId":"NCT04428307","phase":"NA","title":"Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: TESTsmART Aim 2 - Kenya","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-01-11","conditions":["Malaria","Febrile Illness"],"enrollment":5696,"completionDate":"2022-08-31"},{"nctId":"NCT04767217","phase":"PHASE4","title":"Malaria Therapeutic Efficacy Study, Rwanda","status":"COMPLETED","sponsor":"Jhpiego","startDate":"2021-06-14","conditions":["Uncomplicated Malaria"],"enrollment":528,"completionDate":"2024-01-31"},{"nctId":"NCT01868438","phase":"PHASE1","title":"Relative Bioavailability of Pyronaridine-artesunate in Tablet and Granule Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2013-05","conditions":["Malaria"],"enrollment":60,"completionDate":"2014-01"},{"nctId":"NCT01523002","phase":"PHASE1","title":"Drug Interaction Study of Pyronaridine-artesunate & Metoprolol, & Redosing Study of Pyronaridine-artesunate","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2012-01","conditions":["Malaria"],"enrollment":56,"completionDate":"2012-10"},{"nctId":"NCT04767191","phase":"PHASE4","title":"Malaria Therapeutic Efficacy Study (TES) Kenya","status":"COMPLETED","sponsor":"Jhpiego","startDate":"2021-03-15","conditions":["Uncomplicated Malaria"],"enrollment":400,"completionDate":"2022-12-18"},{"nctId":"NCT05478954","phase":"PHASE4","title":"Chemoprevention Efficacy Study in Burkina Faso","status":"UNKNOWN","sponsor":"Malaria Consortium","startDate":"2022-07-15","conditions":["Malaria"],"enrollment":800,"completionDate":"2023-12-01"},{"nctId":"NCT04330690","phase":"PHASE3","title":"Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial","status":"UNKNOWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2020-03-18","conditions":["COVID-19"],"enrollment":2900,"completionDate":"2024-05-18"},{"nctId":"NCT05958810","phase":"","title":"TES of Artemether-lumefantrine for Pf in the Philippines in 2017-2018","status":"COMPLETED","sponsor":"Research Institute for Tropical Medicine, Philippines","startDate":"2017-01-02","conditions":["Malaria,Falciparum","Malaria Recrudescence"],"enrollment":80,"completionDate":"2018-12-28"},{"nctId":"NCT05958693","phase":"","title":"TES of Artemether-lumefantrine for Pf in the Philippines in 2015","status":"COMPLETED","sponsor":"Research Institute for Tropical Medicine, Philippines","startDate":"2015-01-05","conditions":["Malaria,Falciparum","Malaria Recrudescence"],"enrollment":82,"completionDate":"2015-12-30"},{"nctId":"NCT04222088","phase":"","title":"TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014","status":"COMPLETED","sponsor":"Research Institute for Tropical Medicine, Philippines","startDate":"2013-05-01","conditions":["Malaria","Falciparum Malaria","Vivax Malaria","Malaria Recrudescence"],"enrollment":159,"completionDate":"2014-12-30"},{"nctId":"NCT04944966","phase":"PHASE2","title":"Safety and Efficacy of Maytenus Senegalensis for the Treatment of Uncomplicated Malaria","status":"COMPLETED","sponsor":"Ifakara Health Institute","startDate":"2021-06-02","conditions":["Malaria"],"enrollment":12,"completionDate":"2022-09-25"},{"nctId":"NCT02786589","phase":"PHASE1,PHASE2","title":"Plasmodium Immunotherapy for Lung Cancer","status":"UNKNOWN","sponsor":"State Key Laboratory of Respiratory Disease","startDate":"2016-06-27","conditions":["Lung Cancer, Nonsmall Cell"],"enrollment":30,"completionDate":"2023-12-30"},{"nctId":"NCT03813108","phase":"NA","title":"Safety and Efficacy of NF135 CPS Immunization","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2019-04-01","conditions":["Malaria,Falciparum","Controlled Human Malaria Infection","Immunization; Infection"],"enrollment":43,"completionDate":"2021-02-01"},{"nctId":"NCT04713631","phase":"PHASE2","title":"Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease","status":"UNKNOWN","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2021-01-21","conditions":["Crohn's Disease"],"enrollment":40,"completionDate":"2024-01"},{"nctId":"NCT05829187","phase":"PHASE2","title":"Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency","status":"COMPLETED","sponsor":"Syamsudin Abdillah,Ph.D, Pharm D","startDate":"2022-11-01","conditions":["Uncomplicated Plasmodium Falciparum"],"enrollment":36,"completionDate":"2022-12-31"},{"nctId":"NCT00682630","phase":"PHASE1","title":"Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-09","conditions":["Malaria"],"enrollment":42,"completionDate":"2008-09"},{"nctId":"NCT01156389","phase":"PHASE1","title":"Pyronaridine Artesunate-Ritonavir Drug-drug Interaction Study","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2010-07","conditions":["Malaria"],"enrollment":34,"completionDate":"2010-09"},{"nctId":"NCT04708496","phase":"PHASE4","title":"Optimizing Malaria Treatment for HIV-Malaria Co-infected Individuals","status":"UNKNOWN","sponsor":"Makerere University","startDate":"2021-01-18","conditions":["HIV Coinfection","Malaria"],"enrollment":888,"completionDate":"2024-03"},{"nctId":"NCT05605925","phase":"PHASE4","title":"Ivermectin-artemisinin Combination Therapy for Eradication of Malaria","status":"UNKNOWN","sponsor":"Makerere University","startDate":"2022-08-04","conditions":["Malaria"],"enrollment":138,"completionDate":"2022-12-31"},{"nctId":"NCT02633098","phase":"PHASE2","title":"A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer","status":"UNKNOWN","sponsor":"St George's, University of London","startDate":"2017-04-26","conditions":["Colorectal Cancer","Bowel Cancer"],"enrollment":200,"completionDate":"2025-10-31"},{"nctId":"NCT04802382","phase":"PHASE3","title":"Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19","status":"UNKNOWN","sponsor":"MGC Pharmaceuticals d.o.o","startDate":"2021-06-11","conditions":["Corona Virus Infection","Covid19","SARS-CoV Infection"],"enrollment":252,"completionDate":"2023-04"},{"nctId":"NCT03355664","phase":"PHASE3","title":"Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-03-19","conditions":["Malaria, Falciparum"],"enrollment":310,"completionDate":"2020-03-04"},{"nctId":"NCT03952650","phase":"PHASE1,PHASE2","title":"Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-05-23","conditions":["Malaria"],"enrollment":252,"completionDate":"2021-02-10"},{"nctId":"NCT00495508","phase":"PHASE4","title":"Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy","status":"COMPLETED","sponsor":"Epicentre","startDate":"2006-10","conditions":["Malaria"],"enrollment":300,"completionDate":"2009-06"},{"nctId":"NCT00331136","phase":"PHASE2","title":"Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2006-06","conditions":["Uncomplicated Plasmodium Falciparum Malaria"],"enrollment":60,"completionDate":"2006-12"},{"nctId":"NCT04387240","phase":"PHASE2","title":"Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19","status":"WITHDRAWN","sponsor":"Princess Nourah Bint Abdulrahman University","startDate":"2022-01","conditions":["Covid 19 Positive","Corona Virus Infection"],"enrollment":0,"completionDate":"2022-12"},{"nctId":"NCT05340153","phase":"PHASE4","title":"Efficacy and Safety of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine in Cameroon","status":"UNKNOWN","sponsor":"University of Yaounde 1","startDate":"2022-04-11","conditions":["Malaria"],"enrollment":184,"completionDate":"2022-12-31"},{"nctId":"NCT04897919","phase":"PHASE4","title":"Effectiveness and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for Treating Malaria","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2015-08-01","conditions":["Malaria","Effectiveness"],"enrollment":474,"completionDate":"2018-12-01"},{"nctId":"NCT05192265","phase":"PHASE2,PHASE3","title":"Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine","status":"COMPLETED","sponsor":"University of Ibadan","startDate":"2019-05-20","conditions":["Malaria Fever","Plasmodium Falciparum Malaria","Uncomplicated Malaria"],"enrollment":172,"completionDate":"2020-12-23"},{"nctId":"NCT04053907","phase":"NA","title":"P. Falciparum Infection Dynamics and Transmission to Inform Elimination","status":"UNKNOWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-08-15","conditions":["Malaria"],"enrollment":4000,"completionDate":"2022-05-31"},{"nctId":"NCT04265573","phase":"","title":"Feasibility, Acceptability and Costs of a Multiple First-lines Artemisinin-based Combination Therapies","status":"COMPLETED","sponsor":"Groupe de Recherche Action en Sante","startDate":"2018-11-10","conditions":["Malaria"],"enrollment":150000,"completionDate":"2021-02-25"},{"nctId":"NCT05273242","phase":"PHASE4","title":"Add-on Study on WHO Solidarity Trial Plus for COVID-19 in Nepal","status":"UNKNOWN","sponsor":"Nepal Health Research Council","startDate":"2021-12-06","conditions":["COVID-19"],"enrollment":400,"completionDate":"2022-12"},{"nctId":"NCT01054248","phase":"PHASE3","title":"Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-02-16","conditions":["Malaria"],"enrollment":511,"completionDate":"2016-09"},{"nctId":"NCT03167242","phase":"PHASE2","title":"Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-02","conditions":["Acute Uncomplicated Plasmodium Falciparum Malaria"],"enrollment":524,"completionDate":"2021-06-28"},{"nctId":"NCT04618523","phase":"PHASE4","title":"Safety and Efficacy of Recommended Antimalarial in the Democratic Republic of the Congo","status":"COMPLETED","sponsor":"Ministry of Public Health, Democratic Republic of the Congo","startDate":"2020-10-26","conditions":["Malaria"],"enrollment":1117,"completionDate":"2022-02-08"},{"nctId":"NCT04368910","phase":"PHASE3","title":"Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria","status":"TERMINATED","sponsor":"Medicines for Malaria Venture","startDate":"2007-09-06","conditions":["Malaria"],"enrollment":30,"completionDate":"2010-11-15"},{"nctId":"NCT04374019","phase":"PHASE2","title":"Novel Agents for Treatment of High-risk COVID-19 Positive Patients","status":"TERMINATED","sponsor":"Susanne Arnold","startDate":"2020-05-01","conditions":["COVID","Sars-CoV2"],"enrollment":13,"completionDate":"2022-01-12"},{"nctId":"NCT05081089","phase":"PHASE2","title":"Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2021-10-12","conditions":["Malaria,Falciparum"],"enrollment":80,"completionDate":"2022-01-13"},{"nctId":"NCT03465280","phase":"","title":"Airway Intervention Registry (AIR): Recurrent Respiratory Papillomatosis (RRP)","status":"UNKNOWN","sponsor":"Newcastle-upon-Tyne Hospitals NHS Trust","startDate":"2018-04-01","conditions":["Recurrent Respiratory Papillomatosis","Human Papilloma Virus"],"enrollment":400,"completionDate":"2022-08-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Spray","formulations":[{"form":"SPRAY, SUSPENSION","route":"ORAL","productName":"ArtemiC Rescue"}]},"crossReferences":{"NDDF":"019140","UNII":"9RMU91N5K2","CHEBI":"CHEBI:223316","INN_ID":"5954","RXNORM":"2367409","UMLSCUI":"C0052430","ChEMBL_ID":"CHEMBL567597","KEGG_DRUG":"D02481","DRUGBANK_ID":"DB13132","PUBCHEM_CID":"68827","SNOMEDCT_US":"895350006","IUPHAR_LIGAND_ID":"9954","MESH_SUPPLEMENTAL_RECORD_UI":"C031327"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":8763,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"P01BE01","allCodes":["P01BE01","P01BF07","P01BF08"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 27","pmid":"41903303","title":"Artesunate protects against ischemic stroke through THBS2/CD36/TLR4 pathway.","journal":"International immunopharmacology"},{"date":"2026 Mar 3","pmid":"41901260","title":"NovelHTI: An Interpretable Pathway-Enhanced Framework for De Novo Target Prediction of Medicinal Herbs via Cross-Scale Heterogeneous Information Fusion.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2026 Mar 17","pmid":"41893529","title":"Evaluating Toxicity and Anti-Osteogenic Activity of Artemisinin-Inspired Endoperoxides in Zebrafish Larvae.","journal":"Toxics"},{"date":"2026 Mar 17","pmid":"41891011","title":"Sustained High Prevalence of Multiple Antimalarial Drug Resistance Markers in Uganda in 2023-24.","journal":"medRxiv : the preprint server for health sciences"},{"date":"2026 Mar 18","pmid":"41890835","title":"Recurrent parasitemias with artemisinin partial resistance mutations during the 2024 Ethiopia malaria resurgence: a case series.","journal":"Research square"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Artemisinin, also known as Artemef, is a small molecule drug in the artemisinin class that targets Cytochrome P450 1A2. It is used to treat Falciparum malaria, a severe and potentially life-threatening disease caused by the Plasmodium falciparum parasite. The commercial status of Artemef is unclear, as it is not listed as a patented or generic medication. Artemef works by rapidly killing malaria parasites, but its exact mechanism of action is complex and involves the generation of reactive oxygen species. Further research is needed to fully understand its pharmacokinetics and safety profile.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":5,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:42:43.455665+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}